PET Clinics RSS feed: Current Issue. As the clinical applications of positron emission tomography (PET) increase, the new PET Clinics brings together the combined expertise of leading authorities in the field to provide you incisive clinical reviews on advances in the use of PET and combined PET/CT. Published quarterly, PET Clinics provides concise, practical guidance on the clinical issues you face every day. It examines PET's effectiveness in cancer diagnosis and staging, as well as exploring PET's usefulness in the areas of dementia, myocardial viability, and other conditions. Full-color images featured throughout. Topics covered include Breast Cancer, Alzheimer's Disease and Dementia, Lymphoma, Lung Cancer, Cardiology, Pediatric Applications, Infection and Inflammation. As a bonus of your paid subscription, you will receive full, searchable online access to all issues of PET Clinics, enabling you to quickly find answers to your specific clinical questions.http://www.pet.theclinics.com/?rss=yesElsevier Inc.en © 2009 Published by Elsevier Inc. All rights reserved. PET Clinics1556-859842April 2009 © 2009 Published by Elsevier Inc. All rights reserved. healthpermissions@elsevier.comhttp://www.pet.theclinics.com/article/PIIS1556859809001102/abstract?rss=yesTable of Contents10.1016/S1556-8598(09)00110-2PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2vvihttp://www.pet.theclinics.com/article/PIIS1556859809001114/abstract?rss=yesForthcoming Issues10.1016/S1556-8598(09)00111-4PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2viiviihttp://www.pet.theclinics.com/article/PIIS1556859809001035/abstract?rss=yesProstate cancer continues to be a major public health problem. The incidence of prostate cancer is expected to rise as longevity increases. Imaging of prostate cancer is particularly challenging because of the biological and clinical heterogeneity of the disease. Although PET with [F-18]-fluorodeoxyglucose (FDG) has found important diagnostic and, to some extent, prognostic utility in many cancers, the situation for prostate cancer remains uncertain and controversial. The recent National Oncologic PET Registry data suggest that there may be a role for FDG-PET in prostate cancer. PET is usually and unjustly synonymous with FDG-PET. In fact, there are almost an unlimited number of radiotracers that may be designed for PET imaging interrogation of various disease processes, including cancer.PrefaceHossein Jadvar10.1016/j.cpet.2009.06.004PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2ixixhttp://www.pet.theclinics.com/article/PIIS1556859809000315/abstract?rss=yesCancer diagnosis and therapy are undergoing rapid evolution from the current nonspecific diagnosis and treatment toward patient-specific approach to therapy. Imaging is central in this evolution because it provides accurate information on the presence and extent of disease. Various imaging modalities and methods may be best suited for different phases of the disease. It is best to understand the natural history of disease and its progression to tailor the imaging evaluation appropriately. In this article, we present a brief overview of the natural history of prostate cancer before discussing the role of various imaging tools, including opportunities and challenges, for different clinical phases of this disease.Role of Imaging in Prostate CancerHossein Jadvar, Abass Alavi10.1016/j.cpet.2009.05.003PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2135138http://www.pet.theclinics.com/article/PIIS1556859809000509/abstract?rss=yesThis article discusses MR imaging of the normal prostate and of disease conditions of the prostate including prostatitis, cystic lesions, amyloidosis, calculi, hematospermia, benign prostatic hyperplasia, and malignancy.MR Imaging of the Prostate GlandEkta Gupta, Drew A. Torigian10.1016/j.cpet.2009.05.008PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2139154http://www.pet.theclinics.com/article/PIIS1556859809000303/abstract?rss=yesThe role of positron emission tomography (PET) with [F-18]-fluorodeoxyglucose (FDG) for the imaging evaluation of patients who have cancer has expanded rapidly worldwide. The exact clinical use of PET and PET–computed tomography in prostate cancer is currently being explored. The recent publications summarizing the NOPR findings showed that prostate cancer was one of the most common cancers with patient enrollment. This article first reviews the limited available data on the molecular biology basis of FDG accumulation in prostate cancer, and then briefly reviews the current clinical experience with the use of PET with FDG in the imaging evaluation of prostate cancer.FDG PET in Prostate CancerHossein Jadvar10.1016/j.cpet.2009.05.002PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2155161http://www.pet.theclinics.com/article/PIIS1556859809000297/abstract?rss=yesTumor metabolic imaging has focused largely on the use of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG), because many cancers are highly glycolytic even in aerobic conditions. However, some cancers do not consistently exhibit increased FDG uptake, and therefore imaging of other metabolic pathways, such as amino acid or lipid metabolism, has been explored in cancer. Prostate cancer exhibits increased glycolysis frequently only in late stages of the disease. However, several studies have shown that lipid metabolism is increased even in early stages of the disease. The lipogenic phenotype of prostate cancer can be imaged, among others, with 11C-acetate PET.PET Imaging of Prostate Cancer Using 11C-AcetateJohannes Czernin, Matthias R. Benz, Martin S. Allen-Auerbach10.1016/j.cpet.2009.05.001PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2163172http://www.pet.theclinics.com/article/PIIS1556859809001047/abstract?rss=yesAlthough PET using fludeoxyglucose F 18 (FDG) is a promising modality for metabolic imaging of different tumors, the results in prostate cancer have been somewhat inconsistent. Low FDG avidity of most prostate cancer cells and urinary activity are suggested as the main limitations of FDG PET for the evaluation of prostate cancer. Prostate cancer exhibits increased choline metabolism, which is the rationale for using radiolabeled choline for PET. This article describes the basic concepts of radiolabeled choline regarding pharmacokinetics, radiation dosimetry, synthesis, and biodistribution, in addition to advances concerning clinical PET using 11C- and 18F-choline in primary staging and restaging of prostate cancer patients.PET Imaging of Prostate Cancer Using Radiolabeled CholineMohsen Beheshti, Werner Langsteger10.1016/j.cpet.2009.06.003PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2173184http://www.pet.theclinics.com/article/PIIS1556859809000327/abstract?rss=yesThere are significant limitations in the current options for imaging of patients with prostate carcinoma. Although fluorodeoxyglucose is the mainstay of clinical imaging, many other isotope and tracer combinations can be imaged with PET. One of the strengths of nuclear imaging lies in the variety of radiotracers capable of being imaged. In the last 15 years, various compounds have been studied in the hope of identifying the ideal imaging agent for prostate cancer. In this article, the use of imaging agents other than fluorodeoxyglucose, choline, and acetate is discussed.PET Imaging of Prostate Cancer: Other TracersEric M. Rohren, Homer A. Macapinlac10.1016/j.cpet.2009.05.004PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2185192http://www.pet.theclinics.com/article/PIIS1556859809000339/abstract?rss=yesPET imaging has become an integral component of the diagnosis and management of a substantial number of lymphatic and solid malignancies. One of the greatest dilemmas in prostate cancer remains the need for greater personalization of treatment recommendations based on the true extent of disease, so that patients with extraprostatic, micrometastatic disease can be identified early and managed accordingly. These sites currently remain under the level of detection with standard imaging and continue to confound clinicians. Novel PET tracers to complement anatomic data from CT and MR imaging can truly make a difference, and ongoing research holds the greatest promise.PET and Radiation Therapy Planning and Delivery for Prostate CancerNeha Vapiwala, Alexander Lin10.1016/j.cpet.2009.05.005PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2193207http://www.pet.theclinics.com/article/PIIS1556859809001138/abstract?rss=yesIndex10.1016/S1556-8598(09)00113-8PET Clinics 4, 2 (2009)2009-04-01PET Clinics2009-04-0142S1556-8598(09)X0005-2209211